Conclusion:
Research on COVID-19-related treatment can guide clinicians in their
practice. This study, in addition to several others published in the
literature, proves that COVID-19 monoclonal antibodies, such as
Sotrovimab, are effective against COVID-19 infection when given early in
the course of the disease, and may contribute to preventing mortality
and complications in high-risk individuals. This study paves the way to
conduct larger trials on special groups of subjects with
immune-compromising conditions and, to study groups that represent the
population, in order to further assess the benefit of monoclonal
antibodies and identify patients who would benefit the most from their
use. The availability of Sotrovimab at our hospital was made possible
through a generous donation and its use generated positive outcomes.
This emphasizes the need to support low-income countries so that
patients around the world can benefit from the therapeutic advances made
in the management of COVID-19.